SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Corporation Release: Recruitment Complete for Trajenta ® (linagliptin) Cardiovascular Outcome Study in Patients With Type 2 Diabetes